https://www.selleckchem.com/pr....oducts/lonafarnib-sc
Since 2000, medical treatment for epilepsy and cardiovascular risk-reduction strategies have advanced significantly in the United States (US). However, seizure-free rates remain unchanged, and people with epilepsy are at higher risk than the general population for heart disease and stroke. The purpose of this study is to determine how cardiovascular, epilepsy-related, and other causes of death are changing in epilepsy in comparison with the US population. Changes in the 15 underlying causes of death in epilepsy (ICD-10 G40-G
Like
Comment
Share
